Hunan Warrant Pharmaceutical Co. Ltd. A (SHG:688799) — Market Cap & Net Worth
Market Cap & Net Worth: Hunan Warrant Pharmaceutical Co. Ltd. A (688799)
Hunan Warrant Pharmaceutical Co. Ltd. A (SHG:688799) has a market capitalization of $922.00 Million (CN¥6.30 Billion) as of October 14, 2026. Listed on the SHG stock exchange, this China-based company holds position #9189 globally and #2281 in its home market, demonstrating a -12.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Warrant Pharmaceutical Co. Ltd. A's stock price CN¥47.98 by its total outstanding shares 131320000 (131.32 Million).
Hunan Warrant Pharmaceutical Co. Ltd. A Market Cap History: 2021 to 2026
Hunan Warrant Pharmaceutical Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $740.52 Million to $922.00 Million (-0.99% CAGR). Check Hunan Warrant Pharmaceutical Co. Ltd. A stock quote for real-time trading data and today's change.
Hunan Warrant Pharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Warrant Pharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Hunan Warrant Pharmaceutical Co. Ltd. A cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.57x
Hunan Warrant Pharmaceutical Co. Ltd. A's market cap is 0.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.90x
Hunan Warrant Pharmaceutical Co. Ltd. A's market cap is 4.90 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $740.52 Million | $1.15 Billion | $160.76 Million | 0.65x | 4.61x |
| 2022 | $585.43 Million | $1.29 Billion | $182.80 Million | 0.45x | 3.20x |
| 2023 | $920.90 Million | $1.43 Billion | $211.32 Million | 0.64x | 4.36x |
| 2024 | $804.78 Million | $1.41 Billion | $164.32 Million | 0.57x | 4.90x |
Competitor Companies of 688799 by Market Capitalization
Companies near Hunan Warrant Pharmaceutical Co. Ltd. A in the global market cap rankings as of October 14, 2026. See Hunan Warrant Pharmaceutical Co. Ltd. A balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to Hunan Warrant Pharmaceutical Co. Ltd. A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #528 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #580 globally with a market cap of $46.89 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #643 globally with a market cap of $42.48 Billion USD ( CN¥290.31 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #528 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #580 | GALDERMA GROUP AG | NYSE:GALDY | $46.89 Billion | $40.22 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #643 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.48 Billion | CN¥45.51 |
Hunan Warrant Pharmaceutical Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Hunan Warrant Pharmaceutical Co. Ltd. A's market cap moved from $740.52 Million to $ 922.00 Million, with a yearly change of -0.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥922.00 Million | +0.59% |
| 2025 | CN¥916.61 Million | +13.90% |
| 2024 | CN¥804.78 Million | -12.61% |
| 2023 | CN¥920.90 Million | +57.30% |
| 2022 | CN¥585.43 Million | -20.94% |
| 2021 | CN¥740.52 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 14th, 2026 the market cap of Hunan Warrant Pharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $922.00 Million USD |
| MoneyControl | $922.00 Million USD |
| MarketWatch | $922.00 Million USD |
| marketcap.company | $922.00 Million USD |
| Reuters | $922.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hunan Warrant Pharmaceutical Co. Ltd. A
Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products. It offers medicines in the areas of digestive, berating, anti-infection, gynecology, cardiovascular, cerebrovascular, immunology and nephrology, and other fields. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.